Presenting treatment options to men with clinically localized prostate cancer: The acceptability of active surveillance/monitoring

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 191-196

  Donovan, Jenny L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING; TUMOR LOCALIZATION; ATTITUDE TO HEALTH; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DECISION SUPPORT SYSTEM; MALE; PROSTATE TUMOR; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; WATCHFUL WAITING;

DECISION MAKING; DECISION SUPPORT TECHNIQUES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84871783388     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs030     Document Type: Article

References (42)

1. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9(5):445-452.
2. Donovan JL, Frankel SJ, Faulkner A, Selley S, Gillatt D, Hamdy FC. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ. 1999;318(7179):299-300.
3. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283(24):3217-3222.
4. Hanna CL, Mason MD, Donovan JL, Barber JP. Clinical oncologists favour radical radiotherapy for localized prostate cancer: a questionnaire survey. BJU Int. 2002;90(6):558-560.
5. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-990.
6. Chodak GW, Warren KS. Watchful waiting for prostate cancer: a review article. Prostate Cancer Prostatic Dis. 2006;9(1):25-29.
7. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.
8. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274(8):626-631.
9. Johannson JE, Holberg L, Johansson S, Bergsrom R, Adami HO. Fifteen year survival in prostate cancer: a prospective population-based study in Sweden. JAMA. 1997;277(6):467-471.
10. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095-2101.
11. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
12. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol. 2006;176(2):439-449.
13. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23(32):8165-8169.
14. Bastian PJ, Carter BH, Bjartell A, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009;55(6):1321-1330.
15. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep. 2010;11(3):165-171.
16. Dall'Era MA, Konety BR. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nat Clin Pract Urol. 2008;5(5):277-283.
17. Bill-Axelson A, Holmberg L, Ruutu M, et al.; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-1717.
18. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
19. Andriole GL, Crawford ED, Grubb RL III, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
20. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
21. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Ann of Intern Med. 2011;155(11):762-771.
22. Steineck G, Helgesen F, Adolfsson J, et al.; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790-796.
23. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate Cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81-87.
24. National Institutes of Health State-of-the-Science Conference statement: role of active surveillance in the management of men with localized prostate cancer. NIH Consensus Development Program Web site. http://consensus.nih.gov/2011/docs/prostate/ASPC%20Final%20 Draft%20Statement.pdf. Published December 7, 2011. Accessed July 6, 2012.
25. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010;46(17):3095-3101.
26. Donovan JL, Hamdy FC, Neal DE, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1-88.
27. Donovan JL, Peters TJ, Noble S, et al.; ProtecT Study Group. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol. 2003;56(7):605-609.
28. Donovan J, Mills N, Smith M, et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ. 2002;325(7367):766-770.
29. Glaser BG, Strauss AL. The Discovery of Grounded Theory: Strategies for Qualitative Research. Piscataway, NJ: Aldine Transaction; 1967.
30. Miles MB, Huberman AM. Qualitative Data Analysis: An Expanded Sourcebook. London, UK: Sage; 1994.
31. Drew P, Chatwin J, Collins S. Conversation analysis: a method for research into interactions between patients and health-care professionals. Health Expect. 2001;4(1):58-70.
32. Donovan JL, Lane JA, Peters TJ, et al.; ProtecT Study Group. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol. 2009;62(1):29-36.
33. Wolf AM, Wender RC, Etzioni RB, et al.; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.
34. McNaughton-Collins MF, Barry MJ. One man at a time-resolving the PSA controversy. N Engl J Med. 2011;365(21):1951-1953.
35. Hoffman RM, Couper MP, Zikmund-Fisher BJ, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009;169(17):1611-1618.
36. Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med. 2007;33(5):428-434.
37. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology. 2004;63(4):751-756.
38. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F; SCRN Communication Team. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100(3):544-551.
39. Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA. Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol. 2011;64(10):1127-1136.
40. Bowling A, Rowe G. "You decide doctor." What do patient preference arms in clinical trials really mean? J Epidemiol Community Health. 2005;59(11):914-915.
41. King M, Nazareth I, Lampe F, et al. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. Health Technol Assess. 2005;9(35):1-186, iii.
42. Wade J, Donovan JL, Lane JA, Neal DE, Hamdy FC. It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. Soc Sci Med. 2009;68(11):2018-2028.